CT
Cytosorbents Corporation
CTSO · NASDAQ
$3.79 +1.61% (+$0.06)
1M -40.87%
Market Cap $11.7M
P/E Ratio -
Div. Yield -
ROE 445.14%
Bulios Fair Price
$4.17
10.0% upside
Current Price
$3.79
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CTSO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/S 0.31x
PEG N/A
P/E N/A
Growth
24 /100
Declining Book val. growth 44.95%
Rev. growth 2.23%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 33.37%
Gross margin 71.61%
FCF margin 28.01%
Quality
12 /100
Poor ROA 47.98%
ROIC 42.38%
Asset turnover 0.98x
Debt
7 /100
High Int. coverage -11.05x
Current ratio 0.66x
Debt/Assets N/A
Stability
58 /100
Moderate EPS volatility 26.25%
Beta 1.37x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CTSO
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Phillip Chan
Employees
129
Headquarters
Princeton
Upcoming events
12 NOV
Earnings
Upcoming earnings report